Smart PSA Screening for Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen byPeter Gann, MD, ScD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Illinois at Chicago

No Placebo Group

Trial Summary

What is the purpose of this trial?

This intervention includes the introduction of the Prostate Cancer Working Group (PCWG )Smart PSA Screening Guidelines and implementation of patient navigation/ care coordination for men with elevated PSA (\>4.0 ng/mL). The guidelines include: 1. What age to start? 2. How often to repeat screening? 3. What age to stop? 4. What PSA threshold should trigger a biopsy referral?

Eligibility Criteria

This clinical trial is for male adult patients under the care of primary care physicians (PCPs) employed by MSHC. It's focused on those who might need prostate cancer screening, specifically using PSA levels as an indicator.

Inclusion Criteria

I am a primary care provider at MSHC for adult men.

Treatment Details

Interventions

Smart PSA Screening Study (Behavioural Intervention)

Trial OverviewThe study is testing new guidelines for PSA screening to detect prostate cancer. This includes determining the best age to start and stop screenings, how often they should be done, and what PSA level should prompt a biopsy.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: PCP Evaluation of Smart PSA Screening GuidelinesExperimental Treatment1 Intervention

Completing surveys at baseline, 3, 6, 9 and 12 months